Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72 year-old man patient with polycythemia vera who developed multiple cutaneous squamous cell carcinomas (cSCC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Dermatol
Hlavní autoři: March-Rodriguez, Álvaro, Bellosillo, Beatriz, Álvarez-Larrán, Alberto, Besses, Carles, Pujol, Ramon M, Toll, Agustí
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2019
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7992689/
https://ncbi.nlm.nih.gov/pubmed/33911570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5021/ad.2019.31.2.204
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky